1Justin-Temu M, Damian F, Kinget R, et al. Intravaginal gels as drug delivery systems[J]. J Womens Health (Larchmt), 2004, 13(7) :834- 844.
2Gagne N, Cormier H, Omar RF, et al. Protective effect of a thermoreversible gel against the toxicity of nonoxynol-9[ J ]. Sex Transm Dis, 1999, 26(3):177 - 183.
3D'Cruz OJ, Uckun FM. Gel-microemulsions as vaginal spermicides and intravaginal drug delivery vehicles[J]. Contraception, 2001, 64(2):113- 123.
4El-Gizawy SA, Aglan NI. Formulation and evaluation of metronidazole acid gel for vaginal contraception [ J ]. J Pharm Pharmacol,2003, 55(7) :903 -909.
5Lee CH, Chien YW. Development and evaluation of a mucoadhesive drug delivery system for dual-controlled delivery of nonoxynol-9[J].J Control Release, 1996, 39:93 - 103.
7Owen DH, Dunmire EN, Planys AM, et al. Factors influencing nonoxynol-9 permeation and bioactivity in cervical mucus[ J]. J Control Release, 1999, 60( 1 ) :23 - 24.
8Jain SK, Singh R, Sahu B. Development of a liposome-based contraceptive system for intravaginal administration of progesterone [ J ].Drug Dev Ind Pharm, 1997, 23: 827 - 830.
9Ficicioglu C, Gurbuz B, Tasdemir S, et al. High local endometrial effect of vaginal progesterone gel[J]. Gynecol Endocrinol, 2004, 18(5) :240 - 243.
10Wassen L, Schon K, Holmgren J, et al. Local intravaginal vaccination of the female genitaltract[J]. ScandJImmunol, 1996, 44(4):408 - 414.
